Loading…
Lobbying Spend
—
Filings
124
Firms Hired
9
Active Period
2021–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: DESIMONE CONSULTING, LLC
Issues related to access to medicines and other medical therapies, the development of new medical therapies, pharmaceutical supply chain and regulatory matters regarding the biopharmaceutical industry. Issues related to user fee reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $50,000
Matched citations: H.R.2617
Food and Drug Amendments of 2022
2022 · fourth_quarter · Firm: DESIMONE CONSULTING, LLC
Issues related to access to medicines and other medical therapies, the development of new medical therapies, pharmaceutical supply chain and regulatory matters regarding the biopharmaceutical industry. Issues related to user fee reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $50,000
Matched citations: H.R.7667
Issues related to access to medicines and other medical therapies, the development of new medical therapies, pharmaceutical supply chain and regulatory matters regarding the biopharmaceutical industry. Issues related to user fee reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $50,000
Matched citations: S.4348
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: DESIMONE CONSULTING, LLC
Issues related to access to medicines and other medical therapies, the development of new medical therapies, pharmaceutical supply chain and regulatory matters regarding the biopharmaceutical industry. Issues related to user fee reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $50,000
Matched citations: H.R.2617
Food and Drug Amendments of 2022
2022 · fourth_quarter · Firm: DESIMONE CONSULTING, LLC
Issues related to access to medicines and other medical therapies, the development of new medical therapies, pharmaceutical supply chain and regulatory matters regarding the biopharmaceutical industry. Issues related to user fee reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $50,000
Matched citations: H.R.7667
Issues related to access to medicines and other medical therapies, the development of new medical therapies, pharmaceutical supply chain and regulatory matters regarding the biopharmaceutical industry. Issues related to user fee reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $50,000
Matched citations: S.4348
Inflation Reduction Act of 2022
2022 · third_quarter · Firm: TIBER CREEK GROUP
H.R. 5376 - Build Back Better Act, Subtitle J; Inflation Reduction Act of 2022 (PL 117-169), Subtitle B - Prescription Drug Pricing Reform; issues relating to Medicare Part D and Part B Pricing Reform; Issues related to out-of-pocket caps in Part D.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 5376
Inflation Reduction Act of 2022
2022 · third_quarter · Firm: DESIMONE CONSULTING, LLC
Issues related to access to medicines and other medical therapies, the development of new medical therapies, pharmaceutical supply chain and regulatory matters regarding the biopharmaceutical industry; FY2022 Budget Reconciliation (H.R.5376); PDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: H.R.5376
Inflation Reduction Act of 2022
2022 · third_quarter · Firm: DESIMONE CONSULTING, LLC
Issues related to policy changes to Medicare Part D; FY2022 Budget Reconciliation (H.R.5376).
Client expense: — · Firm income: $50,000
Matched citations: H.R.5376
Food and Drug Amendments of 2022
2022 · third_quarter · Firm: DESIMONE CONSULTING, LLC
Issues related to access to medicines and other medical therapies, the development of new medical therapies, pharmaceutical supply chain and regulatory matters regarding the biopharmaceutical industry; FY2022 Budget Reconciliation (H.R.5376); PDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: H.R.7667
Issues related to access to medicines and other medical therapies, the development of new medical therapies, pharmaceutical supply chain and regulatory matters regarding the biopharmaceutical industry; FY2022 Budget Reconciliation (H.R.5376); PDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: S.4348
Inflation Reduction Act of 2022
2022 · second_quarter · Firm: DESIMONE CONSULTING, LLC
Issues related to policy changes to Medicare Part D; FY2022 Budget Reconciliation (H.R.5376).
Client expense: — · Firm income: $50,000
Matched citations: H.R.5376
Inflation Reduction Act of 2022
2022 · second_quarter · Firm: DESIMONE CONSULTING, LLC
Issues related to access to medicines and other medical therapies, the development of new medical therapies, pharmaceutical supply chain and regulatory matters regarding the biopharmaceutical industry; FY2022 Budget Reconciliation (H.R.5376); PDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: H.R.5376
Food and Drug Amendments of 2022
2022 · second_quarter · Firm: DESIMONE CONSULTING, LLC
Issues related to access to medicines and other medical therapies, the development of new medical therapies, pharmaceutical supply chain and regulatory matters regarding the biopharmaceutical industry; FY2022 Budget Reconciliation (H.R.5376); PDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: H.R.7667
Issues related to access to medicines and other medical therapies, the development of new medical therapies, pharmaceutical supply chain and regulatory matters regarding the biopharmaceutical industry; FY2022 Budget Reconciliation (H.R.5376); PDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: S.4348
Inflation Reduction Act of 2022
2022 · second_quarter · Firm: TIBER CREEK GROUP
H.R. 5376 - Build Back Better Act, Subtitle J, issues relating to Medicare Part D and Part B Pricing Reform; Issues related to out-of-pocket caps in Part D.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5376
Elijah E. Cummings Lower Drug Costs Now Act
2022 · first_quarter · Firm: KLINK CAMPAIGNS, INC
-HR3 -Pharmacy Benefits Manager Reform -Medicare Part B & D -Build Back Better Act
Client expense: — · Firm income: —
Matched citations: HR3
Elijah E. Cummings Lower Drug Costs Now Act
2022 · first_quarter · Firm: THE STRATEGY GROUP, INC.
HR3 Lower Drug Cost legislation, advocacy to protect patient access
Client expense: — · Firm income: —
Matched citations: HR3
Inflation Reduction Act of 2022
2022 · first_quarter · Firm: TIBER CREEK GROUP
H.R. 5376 - Build Back Better Act, Subtitle J, issues relating to Medicare Part D and Part B Pricing Reform; Issues related to out-of-pocket caps in Part D.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 5376
Inflation Reduction Act of 2022
2022 · first_quarter · Firm: DESIMONE CONSULTING, LLC
Issues related to access to medicines and other medical therapies, the development of new medical therapies, pharmaceutical supply chain and regulatory matters regarding the biopharmaceutical industry; PDUFA Reauthorization; FY2022 Budget Reconciliation (H.R.5376).
Client expense: — · Firm income: $40,000
Matched citations: H.R.5376
Inflation Reduction Act of 2022
2022 · first_quarter · Firm: DESIMONE CONSULTING, LLC
Issues related to policy changes to Medicare Part D; FY2022 Budget Reconciliation (H.R.5376).
Client expense: — · Firm income: $40,000
Matched citations: H.R.5376
Elijah E. Cummings Lower Drug Costs Now Act
2021 · fourth_quarter · Firm: KLINK CAMPAIGNS, INC
-HR3 -Pharmaceutical Benefits Manager Reform -Build Back Better Act
Client expense: — · Firm income: $10,000
Matched citations: HR3
Elijah E. Cummings Lower Drug Costs Now Act
2021 · fourth_quarter · Firm: THE STRATEGY GROUP, INC.
HR3 Lower Drug Cost legislation, advocacy to protect patient access
Client expense: — · Firm income: —
Matched citations: HR3
Inflation Reduction Act of 2022
2021 · fourth_quarter · Firm: DESIMONE CONSULTING, LLC
Issues related to policy changes to Medicare Part D; H.R.5376, Build Back Better Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R.5376
Inflation Reduction Act of 2022
2021 · fourth_quarter · Firm: DESIMONE CONSULTING, LLC
Issues related to access to medicines and other medical therapies, the development of new medical therapies, pharmaceutical supply chain and regulatory matters regarding the biopharmaceutical industry; H.R.5376, Build Back Better Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R.5376
Source: Senate LDA